Have a personal or library account? Click to login
The therapeutic effect of ultrasound targeted destruction of schisandrin A contrast microbubbles on liver cancer and its mechanism Cover

The therapeutic effect of ultrasound targeted destruction of schisandrin A contrast microbubbles on liver cancer and its mechanism

Radiology and Oncology
Volume 58 (2024): Issue 2 (June 2024)
By: Xiaohui Wang,  Feng Wang,  Pengfei Dong and  Lin Zhou  
Open Access
|Mar 2024

Figures & Tables

FIGURE 1.

Analytical characterization of Span and polyethylene glycol (Span-PEG) microbubbles loaded with schisandrin A (A) The structure SEM of schisandrin A microbubbles; (B) The particle size distribution; (C) Zeta potential of schisandrin A microbubbles, (n = 6).
Analytical characterization of Span and polyethylene glycol (Span-PEG) microbubbles loaded with schisandrin A (A) The structure SEM of schisandrin A microbubbles; (B) The particle size distribution; (C) Zeta potential of schisandrin A microbubbles, (n = 6).

FIGURE 2.

The Walker-256 cell survival rate of schisandrin A (n = 6; compared with control group [0 μg/mL], **P < 0.01).
The Walker-256 cell survival rate of schisandrin A (n = 6; compared with control group [0 μg/mL], **P < 0.01).

FIGURE 3.

Anti-tumor cell experiment assessment in different groups (n = 6; *Compared with C group, P < 0.01; &Compared with D group, P < 0.01; #Compared with U+D group, P < 0.01)
Anti-tumor cell experiment assessment in different groups (n = 6; *Compared with C group, P < 0.01; &Compared with D group, P < 0.01; #Compared with U+D group, P < 0.01)

FIGURE 4.

The content of schisandrin A in the cells of each group (A. Chromatogram of standard schisandrin A; B. Chromatogram of blank intracellular fluid; C. Chromatogram of blank intracellular solution + standard schisandrin A; D. Chromatogram of the tested intracellular liquid; E. Comparison of drug concentrations between different groups, n = 6; **Compared with C group P < 0.001; ##Compared with D group P < 0.001)
The content of schisandrin A in the cells of each group (A. Chromatogram of standard schisandrin A; B. Chromatogram of blank intracellular fluid; C. Chromatogram of blank intracellular solution + standard schisandrin A; D. Chromatogram of the tested intracellular liquid; E. Comparison of drug concentrations between different groups, n = 6; **Compared with C group P < 0.001; ##Compared with D group P < 0.001)

FIGURE 5.

The changes in tumor size before and after drug treatment detected by Ultrasound images (n = 6; *Compared with Pre-treatment group, P < 0.05; **Compared with Pre-treatment group, P < 0.01).
The changes in tumor size before and after drug treatment detected by Ultrasound images (n = 6; *Compared with Pre-treatment group, P < 0.05; **Compared with Pre-treatment group, P < 0.01).

FIGURE 6.

Detection of serum inflammatory factors (tumor necrosis factor-α [TNF-α], interleukin-6 [IL-6], interleukin-1β [IL-1β]) in different group (n = 6, *Compared with C group, P < 0.01; #Compared with D+U group, P < 0.01; &Compared with M+U group, P < 0.01).
Detection of serum inflammatory factors (tumor necrosis factor-α [TNF-α], interleukin-6 [IL-6], interleukin-1β [IL-1β]) in different group (n = 6, *Compared with C group, P < 0.01; #Compared with D+U group, P < 0.01; &Compared with M+U group, P < 0.01).

FIGURE 7.

Histopathological changes in different groups (division of the tumor cell nucleus [red arrows], hyperplasia of collagen fibers [green arrows], necrosis of tumor cells [yellow arrows], and balloon-like swelling of tumor cells [blue arrows]).
Histopathological changes in different groups (division of the tumor cell nucleus [red arrows], hyperplasia of collagen fibers [green arrows], necrosis of tumor cells [yellow arrows], and balloon-like swelling of tumor cells [blue arrows]).

FIGURE 8.

Immunohistochemical changes in different groups.
Immunohistochemical changes in different groups.

FIGURE 9.

The expression of hypoxia inducible factor-1α (HIF-1α), vascular endothlial growth factor (VEGF) and vascular endothelial growth factor receptor 2 (VEGFR-2) proteins in the tumor tissues (n = 6, *Compared with C group, P < 0.01; #Compared with D+U group, P < 0.01; &Compared with M+U group, P < 0.01)
The expression of hypoxia inducible factor-1α (HIF-1α), vascular endothlial growth factor (VEGF) and vascular endothelial growth factor receptor 2 (VEGFR-2) proteins in the tumor tissues (n = 6, *Compared with C group, P < 0.01; #Compared with D+U group, P < 0.01; &Compared with M+U group, P < 0.01)

FIGURE 10.

Protein expression results of phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway in tumor tissues (n = 6, *Compared with Control, P < 0.05; **Compared with Control, P < 0.01).
Protein expression results of phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway in tumor tissues (n = 6, *Compared with Control, P < 0.05; **Compared with Control, P < 0.01).

Loading rate of schisandrin A in Span and polyethylene glycol (Span-PEG) composite microbubbles

Number of experimentsAbsorbance valueRate of load/%
10.5248.68
20.5368.88
30.5418.96
Mean0.5348.84
SD0.0090.14
DOI: https://doi.org/10.2478/raon-2024-0019 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 221 - 233
Submitted on: Sep 20, 2023
|
Accepted on: Dec 26, 2023
|
Published on: Mar 7, 2024
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
ultrasonic targeted destruction,
schisandrin A contrast microbubbles,
liver cancer,
mechanism of action
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2024 Xiaohui Wang, Feng Wang, Pengfei Dong, Lin Zhou, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 58 (2024): Issue 2 (June 2024)Next article